A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

This study is ongoing, but not recruiting participants.

Study NCT00113412. Last updated on March 21, 2006.

Information provided by Samaritan Pharmaceuticals, Inc

Locations

United States, Florida
BioCollections Worldwide, Inc.
Miami, Florida, United States, 33137
Infectious Disease Research Institute
Tampa, Florida, United States, 33614
Orlando Immunology Center
Orlando, Florida, United States, 32803
Therafirst Medical Centers
Fort Lauderdale, Florida, United States, 33308
United States, Pennsylvania
Anderson Medical Group
Pittsburgh, Pennsylvania, United States, 15206
United States, Texas
Tarant County Infectious Disease
Fort Worth, Texas, United States, 76104
University of Texas Health Science Center
Houston, Texas, United States, 77009

Sponsors and Collaborators

Samaritan Pharmaceuticals, Inc

Investigators

Study Director:

Erasto Saldi, MD

Samaritan Pharmaceuticals, Inc